SEARCH

SEARCH BY CITATION

References

  • 1
    Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, Navasa M, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229236.
  • 2
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arteriolar vasodilatation hypothesis: a proposal for initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:11511157.
  • 3
    Lenz K, Hörtnagl H, Drum LW, Reither H, Schmid R, Schweeweiss B, Laggner A, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 1991; 101:10601067.
  • 4
    Guevara M, Gines P, Fernandes-Esppirrach G, Sort P, Sameron JM, Jimenez W, Arroyo V, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:3541.
  • 5
    Gulber GV, Bilzer M, Gerbes AL. Long term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology 1999; 30:870875.
  • 6
    Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome: long term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996; 41:10541056.
  • 7
    Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, et al. Beneficial effects of 2 day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29:565570.
  • 8
    Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, Batacler R, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:4348.
  • 9
    Gines P, Ortega R, Uriz J, Calhorra B, Cardenas A, De Las Herras D, Jimenez W, et al. Effects of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase II study. Hepatology 2002; 36:941948.
  • 10
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, Abergel A, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2001; 122:923930.
  • 11
    Kaffy F, Borderie C, Chagneau C, Ripault MP, Larziliere I, Silvain C, Beauchant M. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. J Hepatol 1999; 30:174.
  • 12
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:16901697.
  • 13
    Arroyo V, Gines P, Gerber AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23:164175.
  • 14
    Buonamico P, Sabba C, Garcia-Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen JE, et al. Octreotide blunts post-prandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology 1995; 21:134139.
  • 15
    Lin HC, Tasi YT, Huang CG, Meng HC, Lee FY, Wang SS, Lee SH. Effects of octreotide on post-prandial systemic and hepatic hemodynamics in patients with post-necrotic cirrhosis. J Hepatol 1991; 21:424429.
  • 16
    McCormick PA, Seifalian AM, Stansby G, McGann G, Collins P, Chin J, McIntyre N, et al. Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: effects of octreotide. J Hepatol 1993; 17:2027.
  • 17
    Schiedermaier P, Göke B, Sauerbruch T. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS. Am J Gastroenterol 2001; 96:22182224.
    Direct Link:
  • 18
    Moller S, Brinch K, Henriksen JH, Becker V. Effect of octreotide on systemic central and splanchnic hemodynamics in cirrhosis. J Hepatol 1997; 26:10261033.
  • 19
    Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, Garcia P, et al. Octreotide prevents post-prandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21:8894.
  • 20
    Ludwig D, Schadel S, Bruning A, Schiefer B, Stange EF. Forty-eight hour hemodynamic effects of octreotide on post-prandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension. Double-blind, placebo-controlled study. Dig Dis Sci 2000; 45:10191027.
  • 21
    Vorobioff JD, Gamen M, Kravetz D, Picabea E, Villavicencio R, Bordato J, Ruf A. Effects of long-term propranolol and octreotide on post-prandial hemodynamics in cirrhosis. A randomized, controlled trial. Gastroenterology 2002; 122:916922.
  • 22
    Creutzfeld W, Lembcke B, Folsch UR, Schlejer S, Koop I. Effects of somatostatin analogue SMS 201–995 (Sandostatin) on pancreatic secretion in humans. Am J Med 1987; 82:4954.
  • 23
    Chatila R, Ferayorni L, Gupta T, Groszmann R. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000; 31:572576.
  • 24
    Sabat M, Guarner C, Soriano G, Bulbena O, Novella MT, Ortiz J, Ricart E, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998; 43:21842189.
  • 25
    Escorsell A, Carlos Bondi J, Andreu V, Moitinho E, Garcia-Pagan JC, Bosch J, Rodes J. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120:161169.
  • 26
    Malesci A, Tacconi M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of post-prandial glucagon response without major changes in renal function. J Hepatol 1997; 26:816825.
  • 27
    Albillos A, Colombato LA, Lee FY, Groszman RJ. Octreotide ameliorates vasodilation and Na+ retention in portal hypertensive rats. Gastroenterology 1993; 104:575579.
  • 28
    Jonassen TE, Christensen S, Sorensen AM, Marcussen N, Flyvbjerg A, Andreasen F, Petersen JS. Effects of chronic octreotide treatment on renal changes during cirrhosis in rats. Hepatology 1999; 29:13871395.
  • 29
    Wang SS, Lee FY, Wu SL, Hwu CM, Chiew CH, Lee SD, Tsai YT, et al. Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997; 26:11281134.
  • 30
    Gines A, Salmeron JM, Gines P, Jimenez W, Salo J, Piera C, Claria J, et al. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992; 103:18681874.
  • 31
    Ottersen LH, Aagard NK, Kiska-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, Flyvberg A, et al. Effect of a long acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized double-blind controlled trial. Hepatology 2001; 34:471477.
  • 32
    Wiest R, Tsai MH, Groszman RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal hypertensive and control rats. Gastroenterology 2001; 120:975983.
  • 33
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome. A pilot study. Hepatology 2002; 36:374380.